Barber H R
Department of Obstetrics and Gynecology, Lenox Hill Hospital, New York, USA.
J Perinat Med. 2001;29(2):97-111. doi: 10.1515/JPM.2001.014.
Cancers in pregnancy are uncommon but do occur with an average frequency of 1 in 1,000 births. This gives rise to opposing emotional reactions in these women: they are happy they are pregnant, but usually devastated when they hear they have cancer. The major reasons for suspecting that pregnancy adversely affects the clinical course of cancer is the immunologic tolerance that characterizes both conditions. It has been pointed out that normal pregnancy and cancer are the only two biologic conditions in which the antigenic tissues is tolerated by a seemingly intact system. It may be stated that the mechanisms that insure the survival of fetus during pregnancy presumably also favors the progress of the neoplasia. Management requires individualization with careful thought as whether termination is necessary or whether continuing with the pregnancy is possible prior to definitive treatment. The physician's aim must be to cure the cancer and deliver live, healthy infants. This is one question when a joint decision is probably best reached among the obstetrician, surgical and medical oncologists and other disciplines. The life-threatening cancer should be managed both for the diagnosis and treatment as in the non-pregnant state. An early small cancer gives a better prognosis than an advanced cancer. The same holds for the non-pregnant patient. The survival in the non-pregnant patient stage for stage is the same as for the pregnant patient. However, all too often in the pregnant state the cancer is more advanced than in the non-pregnant patient. The disease must be evaluated and treated in full light of its exact location in conjunction with an understanding of the natural history within the context of the pregnancy with the potentially viable unborn infant. Concern that maternal cancer may metastasize to the fetus is not justified from a review of the accumulated literature. Infrequency of fetal involvement has led to speculation about biologic protective mechanisms that may exist for the placenta and the fetus and the role circulatory separation in the placenta and immunologic responses of the fetus may play. The association of cancer in pregnancy represents a major physiologic process for the maintenance of the race and a major pathologic process that accounts for numerous deaths. It presents a controlled growth and an uncontrolled growth in the same host.
孕期癌症并不常见,但确实会发生,平均发生率约为每1000例分娩中有1例。这会在这些女性中引发相反的情绪反应:她们很高兴自己怀孕了,但当得知自己患癌时通常会崩溃。怀疑怀孕会对癌症临床进程产生不利影响的主要原因是这两种情况都具有的免疫耐受。有人指出,正常怀孕和癌症是仅有的两种抗原性组织能被看似完好的系统所耐受的生物学状态。可以说,确保孕期胎儿存活的机制大概也有利于肿瘤的进展。管理需要个体化,要仔细考虑是否有必要终止妊娠,或者在进行确定性治疗之前是否有可能继续妊娠。医生的目标必须是治愈癌症并娩出活的、健康的婴儿。这是一个最好由产科医生、外科和医学肿瘤学家以及其他学科共同做出决定的问题。危及生命的癌症应像在非孕期一样进行诊断和治疗。早期小癌症的预后比晚期癌症要好。非孕期患者也是如此。非孕期患者和孕期患者在相同分期下的生存率是一样的。然而,在孕期,癌症往往比非孕期患者更为晚期。必须根据疾病的确切位置,并结合对孕期内自然病程以及潜在存活的未出生婴儿的了解,对疾病进行全面评估和治疗。从对积累的文献回顾来看,担心母体癌症会转移到胎儿身上是没有依据的。胎儿受累情况罕见,这引发了人们对胎盘和胎儿可能存在的生物保护机制以及胎盘循环分离和胎儿免疫反应可能起的作用的猜测。孕期癌症的关联代表了维持种族延续的一个主要生理过程,也是导致众多死亡的一个主要病理过程。它在同一宿主中呈现出一种受控生长和一种不受控生长。